Streetbeat News

Stock Prices

OPGN

OpGen, Inc. (NASDAQ:OPGN) has entered into an agreement with an institutional investor to exercise existing warrants to purchase up to 10,892,728 common shares at $0.7785 per share. The investor will pay an additional $0.25 per share, resulting in gross proceeds of up to $11.2 million. The company will issue new warrants to the investor, exercisable at $0.336 per share, expiring in 2028.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:40 pm

PMVP

Trading of PMV Pharmaceuticals shares has resumed.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:39 pm

PMVP

PMV Pharmaceuticals' shares have been halted on a circuit breaker to the downside, with the stock now down by 15.4%.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:35 pm

DXCM

Shares of DexCom, Inc. (NASDAQ:DXCM) are trading lower after the FDA announced the establishment of a Digital Health Advisory Committee. The committee, which aims to be fully operational by 2024, will focus on addressing the complexities of digital health technologies. This increased regulatory interest introduces uncertainty for companies like DexCom, potentially impacting their products, market access, and ability to innovate.

Portfolio Pulse from Henry Khederian

October 12, 2023 | 4:35 pm

KR

Over the past 20 years, Kroger (NYSE:KR) has outperformed the market by 1.07% on an annualized basis, producing an average annual return of 8.46%. If an investor had bought $100 of KR stock 20 years ago, it would be worth $493.09 today. The company currently has a market capitalization of $31.78 billion.

Portfolio Pulse from Benzinga Insights

October 12, 2023 | 4:30 pm

PCG

Jim Labenthal announced on CNBC that he has purchased shares in Pacific Gas & Electric Co.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:27 pm

WBA

Walgreens Boots Alliance (WBA) shares are trading higher after the company reported mixed Q4 results.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:24 pm

DVA

LLY

NVO

Novo Nordisk (NVO) halted trials for a potential kidney failure treatment due to early signs of efficacy. The trial's success could impact other drugmakers like Eli Lilly (LLY) and DaVita (DVA). The trial tested semaglutide, an ingredient in Novo's diabetes and weight-loss drugs. Eli Lilly, which makes a similar drug, saw a boost in shares, while DaVita, a dialysis firm, saw a slide in shares.

Portfolio Pulse from Adam Eckert

October 12, 2023 | 4:23 pm

HRL

KHC

LW

MKC

MNST

THS

Packaged food stocks are trading lower as the food at home index prices rose 2.4% year over year in September and 0.1% month over month, down from 0.2% in the previous two months.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:23 pm

ETWO

E2open shares are trading higher after experiencing a dip earlier in the week.

Portfolio Pulse from Benzinga Newsdesk

October 12, 2023 | 4:22 pm